. 2020 Mar 18;40(6):1366–1377. doi: 10.1111/liv.14423

Table 1.

Hepatic BA profile

pmol/mg	WT Ctrl	BSEP KO Ctrl	WT MCD	BSEP MCD
TαMCA	7.2 ± 6.8	34.9 ± 12.1 ^a	17.2 ± 7.7	21.3 ± 3.7
TβMCA	71.0 ± 28.4	319.8 ± 91.8 ^a	149.0 ± 54.8	531.9 ± 54.7 ^b , ^c
ToMCA	11.9 ± 6.5	56.6 ± 10.1 ^a	8.5 ± 4.3	27.8 ± 2.5 ^b , ^c
TCA	50.4 ± 30.0	88.6 ± 37.6	223.8 ± 79.0 ^a	74.1 ± 12.7 ^b
TCDCA	1.0 ± 0.6	9.1 ± 0.1 ^a	3.5 ± 1.2 ^a	3.5 ± 0.5 ^c
TDCA	1.4 ± 0.4	0.03 ± 0.02 ^a	2.5 ± 0.7	0.1 ± 0.07 ^b
TUDCA	2.0 ± 1.3	6.6 ± 3.4 ^a	1.6 ± 0.6	2.4 ± 0.2
TLCA	0.1 ± 0.01	0.08 ± 0.01	0.04 ± 0.01 ^a	0.03 ± 0.01 ^c
αMCA	0.1 ± 0.01	1.0 ± 0.3 ^a	0.05 ± 0.01 ^a	0.1 ± 0.02 ^b , ^c
βMCA	0.5 ± 0.1	7.6 ± 0.8 ^a	0.2 ± 0.1 ^a	12.7 ± 2.4 ^b , ^c
oMCA	0.2 ± 0.1	0.4 ± 0.1	0.07 ± 0.02 ^a	0.4 ± 0.1 ^b
CA	0.2 ± 0 05	0.07 ± 0.03	0.2 ± 0.2	0.07 ± 0.04 ^b
PHBA	2.0 ± 0.5	821.6 ± 270.0 ^a	3.8 ± 2.5	361.3 ± 62.7 ^b , ^c
Total BAs	148.0 ± 73.5	1346.4 ± 363.8 ^a	410.4 ± 149.6 ^a	1035.7 ± 85.5 ^b
TbMCA/Tot.BAs (%)	48.0 ± 19.2	23.7 ± 6.8 ^a	36.2 ± 13.2	51.3 ± 5.3 ^b , ^c
TCA/Tot.BAs (%)	34.1 ± 20.3	6.6 ± 2.8 ^a	54.4 ± 19.2	7.1 ± 1.2 ^b
PHBA/Tot.BAs (%)	1.4 ± 0.4	61.0 ± 20.0 ^a	0.9 ± 0.6	34.9 ± 6.0 ^b , ^c

Data represent means ± SD.

^{^a}

Indicates a significant difference in untreated WT controls (Ctrl).

^{^b}

Indicates a significant difference in MCD‐fed WT.

^{^c}

Indicates a significant difference in BSEP KO Ctrl; P < .05.